effects of glp-1 receptor agonists on neurological complications of diabetes Frontiers GLP-1 Receptor Agonists as Treatments
Description
Peak GLP-1 increases were significantly higher (~32%) after RYGB at both follow-ups (p<0.05)
These findings highlight the importance of targeted therapeutic strategies based on HF phenotypes
Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration
The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period
The GLP-1 Solution: 175+ Strategies, Tips, and Tools to Maximize Your Weight Loss and Feel Your Best on Semaglutide, Tirzepatide, and More
GLP-1 drug interactions may affect medication absorption
